<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108012</url>
  </required_header>
  <id_info>
    <org_study_id>GMB1</org_study_id>
    <nct_id>NCT05108012</nct_id>
  </id_info>
  <brief_title>Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients</brief_title>
  <official_title>The Safety Evaluation of Ex Vivo Activated Haploidentical Natural Killer Cells (NK) in Recurrent Glioblastoma Multiform Patients (Clinical Trial Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma multiforme is one of the most invasive and deadly cancers that progresses&#xD;
      rapidly and leads to death. Surgery with radiotherapy /chemotherapy, as a treatment approach&#xD;
      is ineffective in some cases and is associated with relapse and death. Immunotherapy is a&#xD;
      special strategy that is used as an adjunct therapy in various cancers and among the various&#xD;
      methods of immunotherapy, it seems that cell therapy with NK cells is of special importance.&#xD;
      A previous study conducted at the Royan Research Institute showed that NK cell proliferation&#xD;
      and amplification resulted in the removal of glioblastoma tumor masses in the animal model.&#xD;
      The animals had no evidence of tumor recurrence after treatment, and all tumor-related&#xD;
      complications resolved after treatment. Therefore, in this study, we intend to evaluate the&#xD;
      safety of ex vivo activated cells in 5 patients with glioblastoma multiforme whose disease&#xD;
      has returned after treatment and who have not had any appropriate treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1- patient selection 2- leukapheresis 3- CD56+ cells isolation 4- NK cells activation 5-&#xD;
      assessment of functionality and purity 6- quality control tests 7-NK cell injection in tumor&#xD;
      cavity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>We will enroll 5 patients (3-60 year, both sex, -Lansky performance scale/ Karnofsky performance scale: 70-100%) with recurrent Glioblastoma Multiform. A haploidentical donor will enter for each patient.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity assay</measure>
    <time_frame>4 weeks of last injection</time_frame>
    <description>Toxicity as assessed by NCI CTCAE version 3.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the number and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>From injection time point up to 48 hours</time_frame>
    <description>Safety evaluated by assessing the medical symptoms measurement : Fever ,Hysteria and Convulsion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>2 months after injection</time_frame>
    <description>Safety evaluated by assessing the medical symptoms measurement :Meningitis, Neurological disorders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>From injection time point up to 8 weeks</time_frame>
    <description>Safety evaluated by assessing the medical symptoms measurement :Loss of consciousness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI and MRS from the tumor region</measure>
    <time_frame>1 months after last dose of NK cell injection up to 1 year each 3 months</time_frame>
    <description>Defined tumoral residua and tumor cell recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>After surgery up to an average of 1 year</time_frame>
    <description>Evaluation of patient's life extension followed by NK cell therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will inject the activated NK cells, 1-3 times with weekly interval into tumor cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NK cell therapy</intervention_name>
    <description>Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Age: 3-60 Year -&#xD;
&#xD;
          -  Sex: Both&#xD;
&#xD;
          -  Lansky performance scale/ Karnofsky performance scale: 70-100%&#xD;
&#xD;
          -  Life span expectation: &gt;6 months&#xD;
&#xD;
          -  Hemoglobin: &gt; 10.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mmÂ³&#xD;
&#xD;
          -  Serum total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  No diagnosis of any other invasive cancer within the past 5 years.&#xD;
&#xD;
          -  No concurrent serious medical or psychiatric illness that may interfere with giving&#xD;
             informed consent or conducting this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose MRI and MRS images is in favor of radio necrosis.&#xD;
&#xD;
          -  Due to emergency conditions, the patient can not tolerate the new treatment&#xD;
&#xD;
          -  Lack of a suitable donor or insufficient number of NK cells.&#xD;
&#xD;
          -  Development of a new neurological defect after the first injection&#xD;
&#xD;
          -  Patient death during surgery&#xD;
&#xD;
          -  Closing the reservior for the next injection (if this problem is resolved, the&#xD;
             injections will be done again).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niloufar Shayan Asl, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monire Mohammad, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amirali Hamidieh, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric cell therapy research center, Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marzieh Ebrahimi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zohreh Habibi, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital Medical Center, Tehran University of Medical Science, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abolhossein Shahverdi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marzieh Ebrahimi, PhD</last_name>
    <phone>+98 21 235 62516</phone>
    <email>marzieh.ebrahimi@gmail.com;mebrahimi@royan-rc.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zohreh Habibi, M.D</last_name>
    <phone>+98 912 336 5598</phone>
    <email>z-habibi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan institute</name>
      <address>
        <city>Tehran</city>
        <zip>Postal code:1665659911</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niloufar Shayan Asl, MSc</last_name>
      <phone>+98 21 23 56 25 21</phone>
      <email>niloufar.shayanasl@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Monire Mohammad, MSc</last_name>
      <phone>+98 21 23 56 25 21</phone>
      <email>monirmohamad@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Natural Killer Cells (NK)</keyword>
  <keyword>Glioblastoma Multiform (GBM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

